Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Biocept is a diagnostics & research business based in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Biocept employs 177 staff and has a trailing 12-month revenue of around $50.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $0.55 |
|---|---|
| 52-week range | $0.46 - $2.77 |
| 50-day moving average | $0.63 |
| 200-day moving average | $0.99 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.52 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.55 from 2023-02-01
| 1 week (2023-01-26) | 0.55 |
|---|---|
| 1 month (2023-01-03) | 0.55 |
| 3 months (2022-11-03) | -29.49% |
| 6 months (2022-08-03) | -45.00% |
| 1 year (2022-02-03) | -79.40% |
|---|---|
| 2 years (2021-02-03) | -91.32% |
| 3 years (2020-02-03) | 83.21% |
| 5 years (2018-02-02) | 52.69% |
| Revenue TTM | $50.1 million |
|---|---|
| Gross profit TTM | $23.5 million |
| Return on assets TTM | -17.86% |
| Return on equity TTM | -49.72% |
| Profit margin | -32.99% |
| Book value | $1.61 |
| Market capitalisation | $9.5 million |
TTM: trailing 12 months
We're not expecting Biocept to pay a dividend over the next 12 months.
Biocept's shares were split on a 1:10 basis on 7 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.
Over the last 12 months, Biocept's shares have ranged in value from as little as $0.46 up to $2.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.9644. This would suggest that Biocept's shares are less volatile than average (for this exchange).
Biocept, Inc. , a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
